The influence of cytotoxic drugs on the immunophenotype of blast cells in paediatric B precursor acute lymphoblastic leukaemia

1. Campbell M, Castillo L, Riccheri C, Janic D, Jazbec J, Kaiserova E, et al. ALL ICBFM 2009. A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia. Final version of therapy protocol from August 14 2009. [Internet]. [cited 2023 Mar 15]. Available at https://www.bialaczka.org/wp-content/uploads/2016/10/ALLIC_BFM_2009.pdf CampbellM CastilloL RiccheriC JanicD JazbecJ KaiserovaE ALL ICBFM 2009 A randomized trial of the I-BFM-SG for the management of childhood non-B acute lymphoblastic leukemia. Final version of therapy protocol from August 14 2009. [Internet] [cited 2023 Mar 15]. Available at https://www.bialaczka.org/wp-content/uploads/2016/10/ALLIC_BFM_2009.pdf Search in Google Scholar

2. Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med 2016; 375: 1044–53. doi: 10.1056/nejmoa1605085 MauryS ChevretS ThomasX HeimD LeguayT HuguetF Rituximab in B-lineage adult acute lymphoblastic leukemia N Engl J Med 2016 375 1044 53 10.1056/nejmoa1605085 Open DOISearch in Google Scholar

3. Hayden PJ, Roddie C, Bader P, Basak, GW, Bonig H, Bonini C, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 2022; 33: 259–75. doi: 10.1016/j.annonc.2021.12.003 HaydenPJ RoddieC BaderP BasakGW BonigH BoniniC Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) Ann Oncol 2022 33 259 75 10.1016/j.annonc.2021.12.003 Open DOISearch in Google Scholar

4. Li Y, Moriyama T, Yoshimura S, Zhao X, Li Z, Yang X, et al. PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia. Sci Adv 2022; 8: eadd6403. doi: 10.1126/sciadv.add6403 LiY MoriyamaT YoshimuraS ZhaoX LiZ YangX PAX5 epigenetically orchestrates CD58 transcription and modulates blinatumomab response in acute lymphoblastic leukemia Sci Adv 2022 8 eadd6403 10.1126/sciadv.add6403 Open DOISearch in Google Scholar

5. Yan X, Chen D, Ma X, Wang Y, Guo Y, Wei J, et al. CD58 loss in tumor cells confers functional impairment of CAR T cells. Blood Adv 2022; 6: 5844–56. doi: 10.1182/bloodadvances.2022007891 YanX ChenD MaX WangY GuoY WeiJ CD58 loss in tumor cells confers functional impairment of CAR T cells Blood Adv 2022 6 5844 56 10.1182/bloodadvances.2022007891 Open DOISearch in Google Scholar

6. Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood 2020; 136: 1803–12. doi: 10.1182/blood.2019004043 HungerSP RaetzEA How I treat relapsed acute lymphoblastic leukemia in the pediatric population Blood 2020 136 1803 12 10.1182/blood.2019004043 Open DOISearch in Google Scholar

7. Dworzak MN, Schumich A, Printz D, Pötschger U, Husak Z, Attarbaschi A, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 2008; 112: 3982–88. doi: 10.1182/blood-2008-06-164129 DworzakMN SchumichA PrintzD PötschgerU HusakZ AttarbaschiA CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy Blood 2008 112 3982 88 10.1182/blood-2008-06-164129 Open DOISearch in Google Scholar

8. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, et al. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia 2005; 19: 49–56. doi: 10.1038/sj.leu.2403559 GaipaG BassoG MagliaO LeoniV FainiA CazzanigaG Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection Leukemia 2005 19 49 56 10.1038/sj.leu.2403559 Open DOISearch in Google Scholar

9. Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O, et al. Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom 2008; 74: 150–5. doi: 10.1002/cyto.b.20408 GaipaG BassoG AliprandiS MigliavaccaM VallinotoC MagliaO Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells Cytometry B Clin Cytom 2008 74 150 5 10.1002/cyto.b.20408 Open DOISearch in Google Scholar

10. van der Sluijs-Gelling AJ, van der Velden VHJ, Roeffen ETJM, Veerman AJP, van Wering ER. Immunophenotypic modulation in childhood precursor-BALL can be mimicked in vitro and is related to the induction of cell death. Leukemia 2005; 19: 1845–7. doi: 10.1038/sj.leu.2403911 van der Sluijs-GellingAJ van der VeldenVHJ RoeffenETJM VeermanAJP van WeringER Immunophenotypic modulation in childhood precursor-BALL can be mimicked in vitro and is related to the induction of cell death Leukemia 2005 19 1845 7 10.1038/sj.leu.2403911 Open DOISearch in Google Scholar

11. Chen D, Gerasimčik N, Camponeschi A, Tan Y, Wu Q, Brynjolfsson S, et al. CD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemia. Blood Cancer J 2017; 7: e575. doi: 10.1038/bcj.2017.55 ChenD GerasimčikN CamponeschiA TanY WuQ BrynjolfssonS CD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemia Blood Cancer J 2017 7 e575 10.1038/bcj.2017.55 Open DOISearch in Google Scholar

12. Riether C, Schürch CM, Bührer ED, Hinterbrandner M, Huguenin AL, Hoepner S, et al. CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia. J Exp Med 2017; 214: 359–80. doi: 10.1084/jem.20152008 RietherC SchürchCM BührerED HinterbrandnerM HugueninAL HoepnerS CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia J Exp Med 2017 214 359 80 10.1084/jem.20152008 Open DOISearch in Google Scholar

13. Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open 2020; 4(Suppl 3): e000629. doi: 10.1136/esmoopen-2019-000629 StarzerAM BerghoffAS New emerging targets in cancer immunotherapy: CD27 (TNFRSF7) ESMO Open 2020 4 Suppl 3 e000629 10.1136/esmoopen-2019-000629 Open DOISearch in Google Scholar

14. Aljurf M, Chaudhri NA, Almhareb F, Walter CU, Nounou R, Khalil S, et al. CD34 expression in adult acute lymphoblastic leukemia (ALL) Is a favorable prognostic factor in patients treated with stem cell transplant in first remission. Blood 2011; 118: 4091. doi: 10.1182/blood.v118.21.4091.4091 AljurfM ChaudhriNA AlmharebF WalterCU NounouR KhalilS CD34 expression in adult acute lymphoblastic leukemia (ALL) Is a favorable prognostic factor in patients treated with stem cell transplant in first remission Blood 2011 118 4091 10.1182/blood.v118.21.4091.4091 Open DOISearch in Google Scholar

15. Dakka N, Bellaoui H, Bouzid N, Khattab M, Bakri Y, Benjouad A. CD10 and CD34 expression in childhood acute lymphoblastic leukemia in morocco: clinical relevance and outcome. Pediatr Hematol Oncol 2009; 26: 216–31. doi: 10.1080/07357900902897557 DakkaN BellaouiH BouzidN KhattabM BakriY BenjouadA CD10 and CD34 expression in childhood acute lymphoblastic leukemia in morocco: clinical relevance and outcome Pediatr Hematol Oncol 2009 26 216 31 10.1080/07357900902897557 Open DOISearch in Google Scholar

16. Cario G, Rhein P, Mitlöhner R, Zimmermann M, Bandapalli OR, Romey R, et al. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2014; 99: 103–10. doi: 10.3324/haematol.2013.090225 CarioG RheinP MitlöhnerR ZimmermannM BandapalliOR RomeyR High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol Haematologica 2014 99 103 10 10.3324/haematol.2013.090225 Open DOISearch in Google Scholar

17. Guillaume N, Penther D, Vaida I, Gruson B, Harrivel V, Claisse JF, et al. CD66c expression in B-cell acute lymphoblastic leukemia: strength and weakness. Int J Lab Hematol 2011; 33: 92–6. doi: 10.1111/j.1751-553X.2010.01254.x GuillaumeN PentherD VaidaI GrusonB HarrivelV ClaisseJF CD66c expression in B-cell acute lymphoblastic leukemia: strength and weakness Int J Lab Hematol 2011 33 92 6 10.1111/j.1751-553X.2010.01254.x Open DOISearch in Google Scholar

18. Kiyokawa N, Iijima K, Tomita O, Miharu M, Hasegawa D, Kobayashi K, et al. Significance of CD66c expression in childhood acute lymphoblastic leukemia. Leuk Res 2014; 38: 2–48. doi: 10.1016/j.leukres.2013.10.008 KiyokawaN IijimaK TomitaO MiharuM HasegawaD KobayashiK Significance of CD66c expression in childhood acute lymphoblastic leukemia Leuk Res 2014 38 2 48 10.1016/j.leukres.2013.10.008 Open DOISearch in Google Scholar

19. Consolini R, Legitimo A, Rondelli R, Guguelmi C, Barisone E, Lippi A, et al. Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP). Haematologica 1998; 83: 967–73. PMID: 9864914 ConsoliniR LegitimoA RondelliR GuguelmiC BarisoneE LippiA Clinical relevance of CD10 expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP) Haematologica 1998 83 967 73 9864914 Search in Google Scholar

20. Mitwasi N, Arndt C, Loureiro LR, Kegler A, Fasslrinner F, Berndt N, et al. Targeting CD10 on B-cell leukemia using the universal CAR T-cell platform (UniCAR). Int J Mol Sci 2022; 23: 4912. doi: 10.3390/ijms23094920 MitwasiN ArndtC LoureiroLR KeglerA FasslrinnerF BerndtN Targeting CD10 on B-cell leukemia using the universal CAR T-cell platform (UniCAR) Int J Mol Sci 2022 23 4912 10.3390/ijms23094920 Open DOISearch in Google Scholar

21. Gökbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: Current knowledge and future prospects. Ann Hematol 2004; 83: 201–5. doi: 10.1007/s00277-003-0752-8 GökbugetN HoelzerD Treatment with monoclonal antibodies in acute lymphoblastic leukemia: Current knowledge and future prospects Ann Hematol 2004 83 201 5 10.1007/s00277-003-0752-8 Open DOISearch in Google Scholar

22. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol 2012; 1: 1–7. doi: 10.1186/2162-3619-1-36 WangK WeiG LiuD CD19: a biomarker for B cell development, lymphoma diagnosis and therapy Exp Hematol Oncol 2012 1 1 7 10.1186/2162-3619-1-36 Open DOISearch in Google Scholar

23. Brown PA, Ji L, Xu X, Devidas M, Hogan L, Borowitz JB, et al. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymph-oblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from children’s oncology group study AALL1331. Blood 2019; 134(Suppl 2): LBA-1. doi: 10.1182/blood-2019-132435 BrownPA JiL XuX DevidasM HoganL BorowitzJB A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymph-oblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from children’s oncology group study AALL1331 Blood 2019 134 Suppl 2 LBA-1 10.1182/blood-2019-132435 Open DOISearch in Google Scholar

24. Fabrizio VA, Phillips CL, Lane A, Baggott C, Prabhu S, Egeler E, et al. Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: A Pediatric Real World CAR Consortium Report. Blood Adv 2022; 6: 600–10. doi: 10.1182/bloodadvances.2021005564 FabrizioVA PhillipsCL LaneA BaggottC PrabhuS EgelerE Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: A Pediatric Real World CAR Consortium Report Blood Adv 2022 6 600 10 10.1182/bloodadvances.2021005564 Open DOISearch in Google Scholar

25. Schnitzlein WM, Zuckermann FA. Determination of the specificity of CD45 and CD45R monoclonal antibodies through the use of transfected hamster cells producing individual porcine CD45 isoforms. Vet Immunol Immunopathol 1998; 60: 389–401. doi: 10.1016/S0165-2427(97)00113-X SchnitzleinWM ZuckermannFA Determination of the specificity of CD45 and CD45R monoclonal antibodies through the use of transfected hamster cells producing individual porcine CD45 isoforms Vet Immunol Immunopathol 1998 60 389 401 10.1016/S0165-2427(97)00113-X Open DOISearch in Google Scholar

26. Balasubramanian P, Singh J, Verma D, Kumar R, Bakhshi S, Tanwar P, et al. Prognostic significance of CD45 antigen expression in pediatric acute lymphoblastic leukemia. Blood Cells Mol Dis 2021; 89: 102562. doi: 10.1016/j.bcmd.2021.102562 BalasubramanianP SinghJ VermaD KumarR BakhshiS TanwarP Prognostic significance of CD45 antigen expression in pediatric acute lymphoblastic leukemia Blood Cells Mol Dis 2021 89 102562 10.1016/j.bcmd.2021.102562 Open DOISearch in Google Scholar

27. Zhang Y, Liu Q, Yang S, Liao Q. CD58 Immunobiology at a glance. Front Immunol 2021; 12: 1–20. doi: 10.3389/fimmu.2021.705260 ZhangY LiuQ YangS LiaoQ CD58 Immunobiology at a glance Front Immunol 2021 12 1 20 10.3389/fimmu.2021.705260 Open DOISearch in Google Scholar

28. Zhang X, Voskens CJ, Sallin M, Maniar A, Montes CL, Zhang Y, et al. CD137 promotes proliferation and survival of human B cells. J Immunol 2010; 184: 787–95. doi: 10.4049/jimmunol.0901619 ZhangX VoskensCJ SallinM ManiarA MontesCL ZhangY CD137 promotes proliferation and survival of human B cells J Immunol 2010 184 787 95 10.4049/jimmunol.0901619 Open DOISearch in Google Scholar

29. Pieters R, Schrappe M, Valsecchi MG, Biondi A, de Rossi G, Suppiah R, et al. International collaborative treatment protocol for the infants under one year with acute lymphoblastic or biphenotypic leukemia - INTERFANT 06. 2008; version 11(17 July 2007). Cochrane Central Register of Controlled Trials. Available at: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01834165/full PietersR SchrappeM ValsecchiMG BiondiA de RossiG SuppiahR International collaborative treatment protocol for the infants under one year with acute lymphoblastic or biphenotypic leukemia - INTERFANT 06. 2008; version 11 17 July 2007 Cochrane Central Register of Controlled Trials Available at: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01834165/full Search in Google Scholar

30. Brozic A, Pohar Marinsek Z, Novakovic S, Kloboves Prevodnik V. Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas? Diagn Pathol 2015; 10: 1–10. doi: 10.1186/s13000-015-0427-5 BrozicA Pohar MarinsekZ NovakovicS Kloboves PrevodnikV Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas? Diagn Pathol 2015 10 1 10 10.1186/s13000-015-0427-5 Open DOISearch in Google Scholar

31. Brožič A. [Clonality and antigenic properties of reactive and neoplastic lymphocytic proliferations]. [Slovenian]. Doctoral Dissertation; 2016. [Internet]. Available at: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=84423 BrožičA [Clonality and antigenic properties of reactive and neoplastic lymphocytic proliferations]. [Slovenian] Doctoral Dissertation 2016 [Internet]. Available at: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=slv&id=84423 Search in Google Scholar

32. Team RC. A Language and environment for statistical computing. Vienna: R Foundation for Statistical Computin; 2020. [Internet]. [cited 2023 Feb 15]. Available at: cwww.r-project.org/ TeamRC A Language and environment for statistical computing Vienna R Foundation for Statistical Computin 2020 [Internet]. [cited 2023 Feb 15]. Available at: cwww.r-project.org/ Search in Google Scholar

33. Bezanson J, Edelman A, Karpinski S, Shah VB. Julia: a fresh approach to numerical computing. SIAM Rev 2017; 59: 65–98. doi: 10.1137/141000671 BezansonJ EdelmanA KarpinskiS ShahVB Julia: a fresh approach to numerical computing SIAM Rev 2017 59 65 98 10.1137/141000671 Open DOISearch in Google Scholar

34. Pinheiro J, Bates D, DebRoy S, Sarkar D. Team, R.C. Nlme: Linear and Nonlinear Mixed Effects Models. R Package Version Nov 27 2023. [Internet]. [cited 2023 Dec]. Available at: https://cran.r-project.org/web/packages/nlme/nlme.pdf PinheiroJ BatesD DebRoyS SarkarD Team, R.C. Nlme: Linear and Nonlinear Mixed Effects Models R Package Version Nov 27 2023 [Internet]. [cited 2023 Dec]. Available at: https://cran.r-project.org/web/packages/nlme/nlme.pdf Search in Google Scholar

35. Bates D, Alday P, Kleinschmidt D, Calderón JBS, Noack A, Kelman T, et al. JuliaStats/MixedModels.jl: v2.3.0 (v2.3.0). Zenodo; 2020 [Internet]. [cited 2023 Feb 16]. Available at: https://doi.org/10.5281/ZENODO.3727845 BatesD AldayP KleinschmidtD CalderónJBS NoackA KelmanT JuliaStats/MixedModels.jl: v2.3.0 (v2.3.0). Zenodo 2020 [Internet]. [cited 2023 Feb 16]. Available at: https://doi.org/10.5281/ZENODO.3727845 Search in Google Scholar

36. Peterlin J, Kejžar N, Blagus R. Correct specification of design matrices in linear mixed effects models: tests with graphical representation. TEST 2023; 32: 184–210. doi: 10.1007/s11749-022-00830-1 PeterlinJ KejžarN BlagusR Correct specification of design matrices in linear mixed effects models: tests with graphical representation TEST 2023 32 184 210 10.1007/s11749-022-00830-1 Open DOISearch in Google Scholar

37. Dworzak MN, Gaipa G, Schumich A, Maglia O, Ratei R, Veltroni M, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-study group. Cytometry B Clin Cytom 2010; 78: 147–53. doi: 10.1002/cyto.b.20516 DworzakMN GaipaG SchumichA MagliaO RateiR VeltroniM Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-study group Cytometry B Clin Cytom 2010 78 147 53 10.1002/cyto.b.20516 Open DOISearch in Google Scholar

38. Espinoza-Gutarra MR, Agarwal P, Ferrer L, Czader M, Dave U. Relationship between CD45 expression and outcomes in B lymphoblastic leukemia/lymphoma. Blood 2020; 136(Suppl 1): 24. doi: 10.1182/blood-2020-142085 Espinoza-GutarraMR AgarwalP FerrerL CzaderM DaveU Relationship between CD45 expression and outcomes in B lymphoblastic leukemia/lymphoma Blood 2020 136 Suppl 1 24 10.1182/blood-2020-142085 Open DOISearch in Google Scholar

39. Schwarz H, Valbracht J, Tuckwell J, Von Kempis J, Lotz M. ILA the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood 1995; 85: 1043–52. doi: 10.1182/blood.v85.4.1043.bloodjournal8541043 SchwarzH ValbrachtJ TuckwellJ Von KempisJ LotzM ILA the human 4-1BB homologue, is inducible in lymphoid and other cell lineages Blood 1995 85 1043 52 10.1182/blood.v85.4.1043.bloodjournal8541043 Open DOISearch in Google Scholar

40. Borst J, Hendriks J, Xiao Y. CD27 and CD70 in T cell and B cell activation. Curr Opin Immunol 2005; 17: 275–81. doi: 10.1016/j.coi.2005.04.004 BorstJ HendriksJ XiaoY CD27 and CD70 in T cell and B cell activation Curr Opin Immunol 2005 17 275 81 10.1016/j.coi.2005.04.004 Open DOISearch in Google Scholar

41. Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol Today 2000; 21: 204–6. doi: 10.1016/S0167-5699(00)01605-4 AgematsuK HokibaraS NagumoH KomiyamaA CD27: a memory B-cell marker Immunol Today 2000 21 204 6 10.1016/S0167-5699(00)01605-4 Open DOISearch in Google Scholar

42. Taraban VY, Rowley TF, Kerr JP, Willoughby JE, Johnson PM, Al-Shamkhani A, et al. CD27 costimulation contributes substantially to the expansion of functional memory CD8+ T cells after peptide immunization. Eur J Immunol 2013; 43: 3314–23. doi: 10.1002/eji.201343579 TarabanVY RowleyTF KerrJP WilloughbyJE JohnsonPM Al-ShamkhaniA CD27 costimulation contributes substantially to the expansion of functional memory CD8+ T cells after peptide immunization Eur J Immunol 2013 43 3314 23 10.1002/eji.201343579 Open DOISearch in Google Scholar

43. Vitale LA, He LZ, Thomas LJ, Widger J, Weidlick J, Crocker A, et al. Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia. Clin Cancer Res 2012; 18: 3812–21. doi: 10.1158/1078-0432.CCR-11-3308 VitaleLA HeLZ ThomasLJ WidgerJ WeidlickJ CrockerA Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia Clin Cancer Res 2012 18 3812 21 10.1158/1078-0432.CCR-11-3308 Open DOISearch in Google Scholar

44. Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V, Pieters R, et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 2012; 13: 936–45. doi: 10.1016/S1470-2045(12)70377-7 BiondiA SchrappeM De LorenzoP CastorA LucchiniG GandemerV PietersR Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study Lancet Oncol 2012 13 936 45 10.1016/S1470-2045(12)70377-7 Open DOISearch in Google Scholar